IGM Biosciences (IGMS) PT Lowered to $15 at Morgan Stanley
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Nasdaq ends higher as AI heavyweights rebound ahead of midterm results
- Apple shares slip amid guidance for tightening margins, slowing services growth
- Rising shorts cool U.S. large-cap positioning, cutting liquidation risk: Citi
- Apple's 'unprecedented' memory warning adds fuel to wobbly Micron, SK hynix trade
- Palantir raises 2026 revenue outlook after quarterly revenue nearly doubles on AI
Tweet
Share
E-mailGet Alerts IGMS Hot Sheet
Price: $1.27 --0%
Rating Summary:
3 Buy, 8 Hold, 3 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 8 | Down: 10 | New: 1
Rating Summary:
3 Buy, 8 Hold, 3 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 8 | Down: 10 | New: 1
Join SI Premium – FREE
Morgan Stanley analyst Michael Ulz lowered the price target on IGM Biosciences (NASDAQ: IGMS) to $15.00 (from $20.00) while maintaining a Equalweight rating.
You May Also Be Interested In
- Berenberg Downgrades IONOS (IOS:GY) to Hold
- Forvia SE (FRVIA:FP) PT Raised to EUR13 at Citi
- St. James's Place Plc. (STJ:LN) (STJPF) PT Raised to GBP13.91 at JPMorgan
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
